3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio

Healthcare Dividend Kings Johnson & Johnson, Abbott, and UnitedHealth are highlighted for durable cash flows and dividend growth, including J&J’s 64 consecutive years with a 3% dividend increase this year, and Abbott’s 54 straight years with a 6.8% raise. J&J reported Q1 revenue of $24.1B (+9.9%) and adjusted EPS of $2.70 vs $2.68, upgrading FY revenue forecast to $99.7B–$100.7B. Abbott posted Q1 sales of $11.2B (+7.8%) and raised full-year adjusted EPS guidance to $5.38–$5.58, while UnitedHealth generated $8.9B free cash flow in Q1 (1.4x net income) and expects full-year EPS of >$17.35.

Analysis

This reads more like a quality-screen endorsement than a fresh fundamental catalyst, so the alpha is mostly factor/relative-value, not idiosyncratic. The market mechanism is a steady bid for healthcare cash flows when macro volatility rises: low earnings dispersion, visible capital returns, and self-funded growth tend to compress downside beta and support valuation multiples versus the broader market. Among the three, UNH has the most operating leverage to earnings compounding; JNJ and ABT are the cleaner defensive owns, but their slower growth means the market may cap multiple expansion unless guidance keeps stepping up.

The second-order implication is a rotation within healthcare, not across the whole market. If investors chase dividend safety, XLV should outperform XBI and smaller, balance-sheet-constrained biotech names, while service-heavy names with reimbursement risk stay cheap. ABT’s Exact Sciences dilution is the main near-term watch item: until management proves integration can offset dilution, the stock may trade as a stable compounder rather than a re-rate story.

Contrarian view: these names are already owned for defense, so the easy money is likely gone unless rates fall or guidance surprises higher. The real asymmetry is in UNH, where the business model can still compound faster than the sector, but policy headlines can reverse that in days. For JNJ, legal and patent risk remain the main falsifiers; for ABT, evidence of post-deal margin dilution would cap the thesis over the next 1-2 quarters.

Key Decisions for Investors

• Long UNH / short XBI for 1-3 months: best relative-quality expression if risk appetite weakens; target outperformance of 5-8% with the stop on a sustained biotech/M&A-led XBI squeeze.
• Maintain/accumulate XLV on market pullbacks over the next earnings cycle: this is a defensive beta hedge, not an alpha engine, but it should outperform if real yields stay elevated.
• Pair trade: long UNH vs short JNJ over 3-6 months to express faster EPS compounding and capital deployment at UNH versus the slower-growth, legal-overhang-heavy JNJ; thesis breaks on reimbursement or medical-cost inflation surprises.
• Watch ABT rather than chase immediately: only add after the next quarter confirms Exact Sciences dilution is offset by diagnostics growth and margin stability; otherwise ABT remains a high-quality hold, not a catalyst trade.